 |
|
Chronic Fatigue Syndrome and the Cholinergic Hypothesis—Reply
|
|
| Since this article does not have an abstract, we have provided the first 120 words of the full text and any section headings. |
|
|
|
In Reply: My colleagues and I were not proposing that our study was an exhaustive test of cholinergic mechanisms. However, anticholinesterases are now being used increasingly widely to treat other neurocognitive disorders such as traumatic brain injury and Parkinson disease. This, coupled with other observations in CFS, such as marked sensitivity to the anticholinergic adverse effects of tricyclic antidepressants, findings of cognitive impairment, and previous positive (and negative) trials involving both bethanechol and galantamine, led to a hypothesis that our many coinvestigators found persuasive. Our finding that these patients had measurable cognitive impairment that did not show a response to an anticholinesterase is an invitation for further research; we await a trial such as that recommended by Dr Madill.
C. V. Russell Blacker, MD, FRCPsych
c.v.r.blacker@btinternet.com
Department of Health and Social Sciences
Wonford House Hospital
Exeter, England
Letters Section Editor: Robert M. Golub, MD, Senior Editor.
JAMA. 2004;292:2723.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLES
Chronic Fatigue Syndrome and the Cholinergic Hypothesis
Peter V. Madill
JAMA. 2004;292(22):2723.
EXTRACT
| FULL TEXT
Effect of Galantamine Hydrobromide in Chronic Fatigue Syndrome: A Randomized Controlled Trial
C. V. Russell Blacker, David T. Greenwood, Keith A. Wesnes, Rosamund Wilson, Carol Woodward, Ian Howe, and Tauhid Ali
JAMA. 2004;292(10):1195-1204.
ABSTRACT
| FULL TEXT
|
